When added to statin therapy at the maximum tolerated dose, the PCSK9 inhibitor alirocumab reduced low-density lipoprotein cholesterol levels by 62% and also reduced the rate of occurrence of cardiovascular events.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content